Bank Pictet & Cie Europe AG Sells 4,087 Shares of Medtronic PLC $MDT

Key Points

• Bank Pictet & Cie Europe AG has reduced its stake in Medtronic PLC by 31.8%, selling 4,087 shares during the second quarter, bringing its total holdings to 8,746 shares with a value of approximately $762,000.
• Director William R. Jellison recently purchased 2,500 shares of Medtronic at an average price of $92.37 per share, while EVP Harry Skip Kiil sold 8,605 shares at an average price of $91.58, reflecting significant trading activity among insiders.
• Medtronic announced a quarterly dividend of $0.71 per share, scheduled for payment on October 17th, with a dividend yield of **3.0%**, while setting its FY 2026 guidance at an EPS range of **5.600-5.660**.

Bank Pictet & Cie Europe AG cut its holdings in shares of Medtronic PLC (NYSE:MDT - Free Report) by 31.8% during the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 8,746 shares of the medical technology company's stock after selling 4,087 shares during the quarter. Bank Pictet & Cie Europe AG's holdings in Medtronic were worth $762,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Brighton Jones LLC raised its holdings in shares of Medtronic by 1,368.0% in the 4th quarter. Brighton Jones LLC now owns 39,989 shares of the medical technology company's stock valued at $3,194,000 after purchasing an additional 37,265 shares during the period. Lansforsakringar Fondforvaltning AB publ bought a new stake in shares of Medtronic in the 4th quarter valued at about $2,599,000. Wealth Enhancement Advisory Services LLC raised its holdings in shares of Medtronic by 32.2% in the 4th quarter. Wealth Enhancement Advisory Services LLC now owns 477,719 shares of the medical technology company's stock valued at $38,160,000 after purchasing an additional 116,310 shares during the period. Marcum Wealth LLC raised its holdings in shares of Medtronic by 2.9% in the 1st quarter. Marcum Wealth LLC now owns 7,927 shares of the medical technology company's stock valued at $712,000 after purchasing an additional 225 shares during the period. Finally, First Hawaiian Bank raised its holdings in shares of Medtronic by 12.1% in the 1st quarter. First Hawaiian Bank now owns 25,092 shares of the medical technology company's stock valued at $2,255,000 after purchasing an additional 2,699 shares during the period. 82.06% of the stock is owned by institutional investors.

Insider Buying and Selling

In other news, Director William R. Jellison purchased 2,500 shares of the business's stock in a transaction dated Monday, August 25th. The stock was bought at an average price of $92.37 per share, with a total value of $230,925.00. Following the acquisition, the director owned 5,000 shares in the company, valued at approximately $461,850. The trade was a 100.00% increase in their position. The acquisition was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, EVP Harry Skip Kiil sold 8,605 shares of the company's stock in a transaction that occurred on Wednesday, September 3rd. The stock was sold at an average price of $91.58, for a total transaction of $788,045.90. Following the sale, the executive vice president directly owned 35,615 shares of the company's stock, valued at approximately $3,261,621.70. This trade represents a 19.46% decrease in their position. The disclosure for this sale can be found here. Corporate insiders own 0.26% of the company's stock.

Medtronic Stock Performance

Shares of NYSE:MDT opened at $94.34 on Friday. The company's 50 day moving average price is $92.57 and its two-hundred day moving average price is $88.40. Medtronic PLC has a 12-month low of $79.29 and a 12-month high of $96.25. The firm has a market cap of $121.01 billion, a PE ratio of 25.99, a PEG ratio of 2.48 and a beta of 0.77. The company has a quick ratio of 1.50, a current ratio of 2.01 and a debt-to-equity ratio of 0.54.

Medtronic (NYSE:MDT - Get Free Report) last announced its earnings results on Tuesday, August 19th. The medical technology company reported $1.26 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $1.23 by $0.03. Medtronic had a net margin of 13.63% and a return on equity of 14.61%. The firm had revenue of $8.58 billion for the quarter, compared to analyst estimates of $8.37 billion. During the same quarter in the prior year, the business posted $1.23 EPS. The business's revenue was up 7.7% compared to the same quarter last year. Medtronic has set its FY 2026 guidance at 5.600-5.660 EPS. Equities research analysts predict that Medtronic PLC will post 5.46 earnings per share for the current year.

Medtronic Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Friday, October 17th. Stockholders of record on Friday, September 26th will be issued a dividend of $0.71 per share. This represents a $2.84 dividend on an annualized basis and a dividend yield of 3.0%. The ex-dividend date of this dividend is Friday, September 26th. Medtronic's dividend payout ratio is 78.24%.

Wall Street Analysts Forecast Growth

A number of research analysts recently commented on MDT shares. Mizuho upped their price target on shares of Medtronic from $98.00 to $100.00 and gave the company an "outperform" rating in a research note on Wednesday, July 16th. Wall Street Zen upgraded shares of Medtronic from a "hold" rating to a "buy" rating in a research note on Saturday, August 30th. Morgan Stanley reiterated an "overweight" rating and issued a $107.00 price target (up previously from $98.00) on shares of Medtronic in a research note on Tuesday, July 15th. BTIG Research reiterated a "neutral" rating on shares of Medtronic in a research note on Friday, July 11th. Finally, Leerink Partnrs upgraded shares of Medtronic to a "strong-buy" rating in a research note on Monday, June 16th. One analyst has rated the stock with a Strong Buy rating, eleven have given a Buy rating and eight have given a Hold rating to the company. Based on data from MarketBeat.com, Medtronic has a consensus rating of "Moderate Buy" and an average price target of $102.27.

About Medtronic

Medtronic plc develops, manufactures, and sells device-based medical therapies to healthcare systems, physicians, clinicians, and patients worldwide. Its Cardiovascular Portfolio segment offers implantable cardiac pacemakers, cardioverter defibrillators, and cardiac resynchronization therapy devices; cardiac ablation products; insertable cardiac monitor systems; TYRX products; and remote monitoring and patient-centered software.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.